Signature for the diagnosis of lung cancer aggressiveness and genetic instability
AssigneeCentre National de la Recherche Scientifique (CNRS)
InventorsChristophe Cazaux, Jean-Sébastien Hoffmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosing aggressiveness of a lung cancer in a patient from a lung cancer sample of the patient, comprising: a) detecting in vitro an expression profile of the DNA replication stress signature, the signature comprising the CDC6, CLASPIN, PLK1, and POLQ genes, as well as, optionally, RAD51; b) comparing the the expression profile to a reference expression profile, and d) diagnosing cancer aggressiveness from the comparison. Dedicated microarrays and kits are also described, as well as a method of selecting or adapting a suitable treatment.
Claims14
A method for diagnosing and treating aggressiveness of a lung cancer in a patient, comprising the steps of:
- a) detecting from a biological sample of said patient an expression profile of one or more DNA replication stress gene signature, wherein said one or more DNA replication stress gene signature is selected from the group consisting of CDC6, CLASPIN, PLK1, POLQ and RAD51 genes,
- wherein at least one DNA replication stress gene signature is the CLASPIN gene;
- b) comparing the expression profile of step a) with at least one reference expression profile,
- c) diagnosing aggressiveness of the lung cancer by overexpression of the one or more DNA replication stress gene signature in the biological sample compared with at least one reference expression profile;
- and
- d) administering a chemotherapeutic agent to treat the patient diagnosed with aggressive lung cancer, wherein the chemotherapeutic agent is at least one cytotoxic agent selected from the group consisting of an inhibitor of DNA repair, DNA replication/damage checkpoint and DNA replication licensing/initiation.
Dependencies are inferred from the claim text.